Supportive Care

To prevent bleeding related to stem cell transplant or intense induction and conditioning regimens, prophylactic platelet infusion remains the standard of care, according to a study that compared outcomes for patients who received prophylaxis versus those who did not. Read More ›

Total parenteral nutrition (TPN) continues to be inappropriately used at the end of life in cancer patients, according to a review of home-based TPN reported by researchers from Moffitt Cancer Center in Tampa, Florida, at the 2013 Gastrointestinal Cancers Symposium. Read More ›

Adverse effects (AEs) with regorafenib tend to occur early—during the first treatment cycle—and then quickly taper off. Read More ›

“Sexual and intimacy issues are the white elephant in the room for women with breast cancer,” stated Susan W. Rafte, of the Pink Ribbons Project, Houston, Texas. Read More ›

As healthcare professionals who work with people living with cancer, we often see patients when they are most vulnerable. For many patients, their moments of greatest vulnerability are at the time of diagnosis and while discussing treatment. During such moments, patients typically feel overwhelmed and inundated with a large amount of information to process and assimilate, while at the same time dealing with the emotional impact of a cancer diagnosis. Read More ›

Anticoagulation prophylaxis is effective in preventing both symptomatic and asymptom­atic catheter-related deep vein thrombosis in ambulatory cancer patients with locally advanced or metastatic solid tumors, French investigators reported at the European Society for Medical Oncology (ESMO) 2012 Congress, held in Vienna, Austria. Read More ›

Identifying agents that can prevent chemotherapy-induced peripheral neuropathy (CIPN) is a work in progress. Studies of some interventions suggest modestly encouraging findings, but research on prevention has been hampered by a poor understanding of the different mechanisms of this toxic­ity with the various chemotherapy agents that induce CIPN. Read More ›

Motor toxicities of chemotherapy-induced peripheral neuropathy (CIPN) are likely to lead to falls, deficits in physical performance (PP), and functional losses, according to a substudy of a phase 3 clinical trial in patients with CIPN reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.1

Read More ›

Idiopathic thrombocytopenic purpura (ITP), now more commonly referred to as immune thrombocytopenia, is defined as a hemorrhagic disorder in which there is a pronounced reduction in circulating blood platelets due to the presence in blood plasma of a substance that agglutinates platelets.1 Despite this definition, the risk of bleeding in patients with ITP seems dis proportionately low, compared with the circulating platelet counts.

Read More ›

Regardless of the stage of immune thrombocytopenia (ITP), previously referred to as idiopathic thrombocytopenic purpura, treatment decisions must take into account an individual’s preferences as well as comorbidities, bleeding, the urgency to increase the platelet count, and potential advantages and adverse effects of each treatment.

Read More ›

Page 7 of 13


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: